CONTEXT: Blood-based analytes may be indicators of pathological processes in Alzheimer disease (AD). OBJECTIVE: To identify plasma proteins associated with AD pathology using a combined proteomic and neuroimaging approach. DESIGN: Discovery-phase proteomics to identify plasma proteins associated with correlates of AD pathology. Confirmation and validation using immunodetection in a replication set and an animal model. SETTING: A multicenter European study (AddNeuroMed) and the Baltimore Longitudinal Study of Aging. PARTICIPANTS: Patients with AD, subjects with mild cognitive impairment, and healthy controls with standardized clinical assessments and structural neuroimaging. MAIN OUTCOME MEASURES: Association of plasma proteins with brain atrophy, disease severity, and rate of clinical progression. Extension studies in humans and transgenic mice tested the association between plasma proteins and brain amyloid. RESULTS: Clusterin/apolipoprotein J was associated with atrophy of the entorhinal cortex, baseline disease severity, and rapid clinical progression in AD. Increased plasma concentration of clusterin was predictive of greater fibrillar amyloid-beta burden in the medial temporal lobe. Subjects with AD had increased clusterin messenger RNA in blood, but there was no effect of single-nucleotide polymorphisms in the gene encoding clusterin with gene or protein expression. APP/PS1 transgenic mice showed increased plasma clusterin, age-dependent increase in brain clusterin, as well as amyloid and clusterin colocalization in plaques. CONCLUSIONS: These results demonstrate an important role of clusterin in the pathogenesis of AD and suggest that alterations in amyloid chaperone proteins may be a biologically relevant peripheral signature of AD.
CONTEXT: Blood-based analytes may be indicators of pathological processes in Alzheimer disease (AD). OBJECTIVE: To identify plasma proteins associated with AD pathology using a combined proteomic and neuroimaging approach. DESIGN: Discovery-phase proteomics to identify plasma proteins associated with correlates of AD pathology. Confirmation and validation using immunodetection in a replication set and an animal model. SETTING: A multicenter European study (AddNeuroMed) and the Baltimore Longitudinal Study of Aging. PARTICIPANTS: Patients with AD, subjects with mild cognitive impairment, and healthy controls with standardized clinical assessments and structural neuroimaging. MAIN OUTCOME MEASURES: Association of plasma proteins with brain atrophy, disease severity, and rate of clinical progression. Extension studies in humans and transgenic mice tested the association between plasma proteins and brain amyloid. RESULTS: Clusterin/apolipoprotein J was associated with atrophy of the entorhinal cortex, baseline disease severity, and rapid clinical progression in AD. Increased plasma concentration of clusterin was predictive of greater fibrillar amyloid-beta burden in the medial temporal lobe. Subjects with AD had increased clusterin messenger RNA in blood, but there was no effect of single-nucleotide polymorphisms in the gene encoding clusterin with gene or protein expression. APP/PS1 transgenic mice showed increased plasma clusterin, age-dependent increase in brain clusterin, as well as amyloid and clusterin colocalization in plaques. CONCLUSIONS: These results demonstrate an important role of clusterin in the pathogenesis of AD and suggest that alterations in amyloid chaperone proteins may be a biologically relevant peripheral signature of AD.
Authors: Bruce Fischl; André van der Kouwe; Christophe Destrieux; Eric Halgren; Florent Ségonne; David H Salat; Evelina Busa; Larry J Seidman; Jill Goldstein; David Kennedy; Verne Caviness; Nikos Makris; Bruce Rosen; Anders M Dale Journal: Cereb Cortex Date: 2004-01 Impact factor: 5.357
Authors: Lennart Eriksson; Henrik Antti; Johan Gottfries; Elaine Holmes; Erik Johansson; Fredrik Lindgren; Ingrid Long; Torbjörn Lundstedt; Johan Trygg; Svante Wold Journal: Anal Bioanal Chem Date: 2004-09-22 Impact factor: 4.142
Authors: Sandip Ray; Markus Britschgi; Charles Herbert; Yoshiko Takeda-Uchimura; Adam Boxer; Kaj Blennow; Leah F Friedman; Douglas R Galasko; Marek Jutel; Anna Karydas; Jeffrey A Kaye; Jerzy Leszek; Bruce L Miller; Lennart Minthon; Joseph F Quinn; Gil D Rabinovici; William H Robinson; Marwan N Sabbagh; Yuen T So; D Larry Sparks; Massimo Tabaton; Jared Tinklenberg; Jerome A Yesavage; Robert Tibshirani; Tony Wyss-Coray Journal: Nat Med Date: 2007-10-14 Impact factor: 53.440
Authors: Catherine M L Foy; Helen Nicholas; Paul Hollingworth; Harry Boothby; Julie Willams; Richard G Brown; Safa Al-Sarraj; Simon Lovestone Journal: Int J Geriatr Psychiatry Date: 2007-11 Impact factor: 3.485
Authors: Ralf Baron; Donna M Ferriero; Giovanni B Frisoni; Chetan Bettegowda; Ziya L Gokaslan; John A Kessler; Annamaria Vezzani; Stephen G Waxman; Sven Jarius; Brigitte Wildemann; Michael Weller Journal: Nat Rev Neurol Date: 2015-10-27 Impact factor: 42.937
Authors: Nathan L Hutcheson; David G Clark; Mark S Bolding; David M White; Adrienne C Lahti Journal: Psychiatry Res Date: 2013-10-22 Impact factor: 3.222
Authors: Valerie Yu; Dhruva Bhattacharya; Andrew Webster; Aditi Bauskar; Charles Flowers; Martin Heur; Shravan K Chintala; Tatsuo Itakura; Mark R Wilson; Joseph T Barr; Shinwu Jeong; Mingwu Wang; M Elizabeth Fini Journal: Ocul Surf Date: 2018-08-02 Impact factor: 5.033